A new analysis of more than 30 million FDA adverse event reports has found that Wegovy — the higher-dose version of semaglutide used specifically for weight loss — carries a meaningfully stronger safety signal for a rare eye condition than other semaglutide formulations, including Ozempic.
The condition is called non-arteritic anterior ischemic optic neuropathy, or NAION. It is sometimes described as an "eye stroke." It occurs when blood flow to the optic nerve is reduced or blocked, damaging the nerve that carries visual signals from the eye to the brain. The condition can cause sudden, often permanent, loss of vision in one eye — typically with no warning and no surgical reversal.
